Tags

Type your tag names separated by a space and hit enter

Annona muricata Linn. leaf as a source of antioxidant compounds with in vitro antidiabetic and inhibitory potential against α-amylase, α-glucosidase, lipase, non-enzymatic glycation and lipid peroxidation.
Biomed Pharmacother. 2018 Apr; 100:83-92.BP

Abstract

Annona muricata leaves are used in traditional medicine to manage diabetes mellitus and its complications. The aim of this study was to evaluate the potential in vitro antidiabetic properties of Annona muricata leaf by identifying its main phytochemical constituents and characterizing the phenolic-enriched fractions for their in vitro antioxidant capacity and inhibitory activities against glycoside and lipid hydrolases, advanced glycation end-product formation and lipid peroxidation. Ethanol extract of A. muricata leaf was subjected to a liquid-liquid partitioning and its fractions were used in enzymatic assays to evaluate their inhibitory potential against α-amylase, α-glucosidase and lipase, as well as their antioxidant (DPPH, ORAC, FRAP and Fe2+-ascorbate-induced lipid peroxidation assays) and anti-glycation (BSA-fructose, BSA-methylglyoxal and arginine-methylglyoxal models) capacities. In addition, identification of the main bioactive compounds of A. muricata leaf by HPLC-ESI-MS/MS analysis was carried out. Ethyl acetate (EtOAc) and n-butanol (BuOH) fractions showed, respectively, antioxidant properties (ORAC 3964 ± 53 and 2707 ± 519 μmol trolox eq g-1, FRAP 705 ± 35 and 289 ± 18 μmol trolox eq g-1, and DPPH IC50 4.3 ± 0.7 and 9.3 ± 0.8 μg mL-1) and capacity to reduce liver lipid peroxidation (p < .01). Also, EtOAc and BuOH, respectively, inhibited glycation in BSA-fructose (IC50 45.7 ± 13.5 and 61.9 ± 18.2 μg mL-1), BSA-methylglyoxal (IC50 166.1 ± 21.6 and 413.2 ± 49.5 μg mL-1) and arginine-methylglyoxal (IC50 437.9 ± 89.0 and 1191.0 ± 199.0 μg mL-1) assays, α-amylase (IC50 9.2 ± 2.3 and 6.1 ± 1.6 μg mL-1), α-glucosidase (IC50 413.1 ± 121.1 and 817.4 ± 87.9 μg mL-1) and lipase (IC50 74.2 ± 30.1 and 120.3 ± 50.5 μg.mL-1), and presented lower cytotoxicity, when compared to the other fractions and crude extract. Various biomolecules known as potent antioxidants were identified in these fractions, such as chlorogenic and caffeic acids, procyanidins B2 and C1, (epi)catechin, quercetin, quercetin-hexosides and kaempferol. This study presents new biological activities not yet described for A. muricata, which contributes to the understanding of the potential effectiveness in the use of the A. muricata leaf, especially its polyphenols-enriched fractions, for the management of diabetes mellitus and its complications.

Authors+Show Affiliations

Institute of Biotechnology - Federal University of Uberlândia, Av. Pará, 1720, 38400-902, Uberlândia, MG Brazil.Institute of Biomedical Sciences - Federal University of Uberlândia, Av. Pará, 1720, 38400-902, Uberlândia, MG Brazil.Institute of Biotechnology - Federal University of Uberlândia, Av. Pará, 1720, 38400-902, Uberlândia, MG Brazil.Institute of Chemistry - Federal University of Uberlândia, Av. João Naves de Ávila, 2121, 38408-100, Uberlândia, MG Brazil.Institute of Biomedical Sciences - Federal University of Uberlândia, Av. Pará, 1720, 38400-902, Uberlândia, MG Brazil.Institute of Biotechnology - Federal University of Uberlândia, Av. Pará, 1720, 38400-902, Uberlândia, MG Brazil. Electronic address: foued@ufu.br.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

29425747

Citation

Justino, Allisson Benatti, et al. "Annona Muricata Linn. Leaf as a Source of Antioxidant Compounds With in Vitro Antidiabetic and Inhibitory Potential Against Α-amylase, Α-glucosidase, Lipase, Non-enzymatic Glycation and Lipid Peroxidation." Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, vol. 100, 2018, pp. 83-92.
Justino AB, Miranda NC, Franco RR, et al. Annona muricata Linn. leaf as a source of antioxidant compounds with in vitro antidiabetic and inhibitory potential against α-amylase, α-glucosidase, lipase, non-enzymatic glycation and lipid peroxidation. Biomed Pharmacother. 2018;100:83-92.
Justino, A. B., Miranda, N. C., Franco, R. R., Martins, M. M., Silva, N. M. D., & Espindola, F. S. (2018). Annona muricata Linn. leaf as a source of antioxidant compounds with in vitro antidiabetic and inhibitory potential against α-amylase, α-glucosidase, lipase, non-enzymatic glycation and lipid peroxidation. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 100, 83-92. https://doi.org/10.1016/j.biopha.2018.01.172
Justino AB, et al. Annona Muricata Linn. Leaf as a Source of Antioxidant Compounds With in Vitro Antidiabetic and Inhibitory Potential Against Α-amylase, Α-glucosidase, Lipase, Non-enzymatic Glycation and Lipid Peroxidation. Biomed Pharmacother. 2018;100:83-92. PubMed PMID: 29425747.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Annona muricata Linn. leaf as a source of antioxidant compounds with in vitro antidiabetic and inhibitory potential against α-amylase, α-glucosidase, lipase, non-enzymatic glycation and lipid peroxidation. AU - Justino,Allisson Benatti, AU - Miranda,Natália Carnevalli, AU - Franco,Rodrigo Rodrigues, AU - Martins,Mário Machado, AU - Silva,Neide Maria da, AU - Espindola,Foued Salmen, Y1 - 2018/02/06/ PY - 2017/11/04/received PY - 2018/01/25/revised PY - 2018/01/28/accepted PY - 2018/2/10/pubmed PY - 2018/9/4/medline PY - 2018/2/10/entrez KW - Annonaceae KW - Glycation KW - Natural products KW - Phenolic compounds KW - Soursop KW - Starch hydrolase SP - 83 EP - 92 JF - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie JO - Biomed Pharmacother VL - 100 N2 - Annona muricata leaves are used in traditional medicine to manage diabetes mellitus and its complications. The aim of this study was to evaluate the potential in vitro antidiabetic properties of Annona muricata leaf by identifying its main phytochemical constituents and characterizing the phenolic-enriched fractions for their in vitro antioxidant capacity and inhibitory activities against glycoside and lipid hydrolases, advanced glycation end-product formation and lipid peroxidation. Ethanol extract of A. muricata leaf was subjected to a liquid-liquid partitioning and its fractions were used in enzymatic assays to evaluate their inhibitory potential against α-amylase, α-glucosidase and lipase, as well as their antioxidant (DPPH, ORAC, FRAP and Fe2+-ascorbate-induced lipid peroxidation assays) and anti-glycation (BSA-fructose, BSA-methylglyoxal and arginine-methylglyoxal models) capacities. In addition, identification of the main bioactive compounds of A. muricata leaf by HPLC-ESI-MS/MS analysis was carried out. Ethyl acetate (EtOAc) and n-butanol (BuOH) fractions showed, respectively, antioxidant properties (ORAC 3964 ± 53 and 2707 ± 519 μmol trolox eq g-1, FRAP 705 ± 35 and 289 ± 18 μmol trolox eq g-1, and DPPH IC50 4.3 ± 0.7 and 9.3 ± 0.8 μg mL-1) and capacity to reduce liver lipid peroxidation (p < .01). Also, EtOAc and BuOH, respectively, inhibited glycation in BSA-fructose (IC50 45.7 ± 13.5 and 61.9 ± 18.2 μg mL-1), BSA-methylglyoxal (IC50 166.1 ± 21.6 and 413.2 ± 49.5 μg mL-1) and arginine-methylglyoxal (IC50 437.9 ± 89.0 and 1191.0 ± 199.0 μg mL-1) assays, α-amylase (IC50 9.2 ± 2.3 and 6.1 ± 1.6 μg mL-1), α-glucosidase (IC50 413.1 ± 121.1 and 817.4 ± 87.9 μg mL-1) and lipase (IC50 74.2 ± 30.1 and 120.3 ± 50.5 μg.mL-1), and presented lower cytotoxicity, when compared to the other fractions and crude extract. Various biomolecules known as potent antioxidants were identified in these fractions, such as chlorogenic and caffeic acids, procyanidins B2 and C1, (epi)catechin, quercetin, quercetin-hexosides and kaempferol. This study presents new biological activities not yet described for A. muricata, which contributes to the understanding of the potential effectiveness in the use of the A. muricata leaf, especially its polyphenols-enriched fractions, for the management of diabetes mellitus and its complications. SN - 1950-6007 UR - https://www.unboundmedicine.com/medline/citation/29425747/Annona_muricata_Linn__leaf_as_a_source_of_antioxidant_compounds_with_in_vitro_antidiabetic_and_inhibitory_potential_against_α_amylase_α_glucosidase_lipase_non_enzymatic_glycation_and_lipid_peroxidation_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0753-3322(17)35831-6 DB - PRIME DP - Unbound Medicine ER -